Sökning: onr:"swepub:oai:DiVA.org:uu-317746" >
Intra-image referen...
Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
-
- Sandberg, Dan T (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Tolmachev, Vladimir (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Velikyan, Irina, 1966- (författare)
- Uppsala universitet,Radiologi
-
visa fler...
-
- Olofsson, Helena (författare)
- Uppsala universitet,Klinisk och experimentell patologi
-
- Wennborg, Anders (författare)
- Affibody AB, Solna, Sweden
-
- Feldwisch, Joachim (författare)
- Affibody AB, Solna, Sweden
-
- Carlsson, Jörgen, 1944- (författare)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Sörensen, Jens (författare)
- Uppsala universitet,Radiologi
-
visa färre...
-
(creator_code:org_t)
- 2017-03-06
- 2017
- Engelska.
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 44:8, s. 1337-1346
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: In phase I/II-studies radiolabelled ABY-025 Affibody molecules identified human epidermal growth factor receptor 2 (HER2) expression in breast cancer metastases using PET and SPECT imaging. Here, we wanted to investigate the utility of a simple intra-image normalization using tumour-to-reference tissue-ratio (T/R) as a HER2 status discrimination strategy to overcome potential issues related to cross-calibration of scanning devices.METHODS: Twenty-three women with pre-diagnosed HER2-positive/negative metastasized breast cancer were scanned with [(111)In]-ABY-025 SPECT/CT (n = 7) or [(68)Ga]-ABY-025 PET/CT (n = 16). Uptake was measured in all metastases and in normal spleen, lung, liver, muscle, and blood pool. Normal tissue uptake variation and T/R-ratios were established for various time points and for two different doses of injected peptide from a total of 94 whole-body image acquisitions. Immunohistochemistry (IHC) was used to verify HER2 expression in 28 biopsied metastases. T/R-ratios were compared to IHC findings to establish the best reference tissue for each modality and each imaging time-point. The impact of shed HER2 in serum was investigated.RESULTS: Spleen was the best reference tissue across modalities, followed by blood pool and lung. Spleen-T/R was highly correlated to PET SUV in metastases after 2 h (r = 0.96, P < 0.001) and reached an accuracy of 100% for discriminating IHC HER2-positive and negative metastases at 4 h (PET) and 24 h (SPECT) after injection. In a single case, shed HER2 resulted in intense tracer retention in blood. In the remaining patients shed HER2 was elevated, but without significant impact on ABY-025 biodistribution.CONCLUSION: T/R-ratios using spleen as reference tissue accurately quantify HER2 expression with radiolabelled ABY-025 imaging in breast cancer metastases with SPECT and PET. Tracer binding to shed HER2 in serum might affect quantification in the extreme case.
Nyckelord
- Affibody
- HER2-receptor
- PET
- SPECT
- Shedding
- T/R
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sandberg, Dan T
-
Tolmachev, Vladi ...
-
Velikyan, Irina, ...
-
Olofsson, Helena
-
Wennborg, Anders
-
Feldwisch, Joach ...
-
visa fler...
-
Carlsson, Jörgen ...
-
Lindman, Henrik
-
Sörensen, Jens
-
visa färre...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet